Company / Capital Expenditures
Halozyme Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$7.0M
FY2025
5-year range
$4.0M / $15.3M
FY2021-FY2025
Trend
-34.8%
vs FY2024
Sector context
#66 of 194
Health Care
What the data says
At $7M, Halozyme's capital expenditures ranks #66 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $1M in FY2019 to $15M in FY2023.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +8.4%.
Declined from $15M to $7M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +13.2%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
#66 of 194 in Health CareTop 34% of 194This company $7.0M Sector average $117.5M
▼
-94.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 34.8% year-over-year.
- Ranks #66 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.0M | -34.8% |
| FY2024 | $10.7M | -30.1% |
| FY2023 | $15.3M | +218.0% |
| FY2022 | $4.8M | +19.1% |
| FY2021 | $4.0M | -13.4% |
| FY2020 | $4.7M | +245.4% |
| FY2019 | $1.4M | -71.0% |
| FY2018 | $4.7M | +245.4% |
| FY2017 | $1.4M | -1.3% |
| FY2016 | $1.4M | -40.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026